Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.68 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.68 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.68 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.68 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.68 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1882738 | 0.94 | KDM4E (0.62) | KDM4EGABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL1884350 | 0.92 | KDM4E (0.60) | KDM4EGABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL1871646 | 0.91 | KDM4E (0.59) | KDM4EGABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL1879199 | 0.90 | KDM4E (0.70) | KDM4EGABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL1876103 | 0.90 | KDM4E (0.70) | KDM4EGABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL1874687 | 0.89 | KDM4E (0.62) | KDM4EGABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL1878782 | 0.87 | KDM4E (0.66) | KDM4EGABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL1877361 | 0.86 | KDM4E (0.66) | KDM4EGABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL1871645 | 0.85 | KDM4E (0.58) | KDM4EGABRA1GABRG2GABRB3GABRA2 | |
| SCHEMBL1881248 | 0.84 | KDM4E (0.64) | KDM4EGABRA1GABRG2GABRB3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947688-B2 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2011-05-24 | — | — | US | claimed |
| EP-1648897-B1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INT (ES) | 2008-12-10 | — | — | EP | claimed |
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL S.A. (ES) | 2006-11-30 | — | — | US | claimed |
| US-7947688-B2 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2011-05-24 | — | — | US | disclosed |
| EP-1648897-B1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INT (ES) | 2008-12-10 | — | — | EP | disclosed |
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL S.A. (ES) | 2006-11-30 | — | — | US | disclosed |
| EP-1648897-A1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005014597-A1 | N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | GABRA2, GABRA1, GABRA3 | KDM4E 3264/4885GABRA1 2/4885GABRG2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.